References

ⁱ United States Centers for Disease Control, Department of Viral Hepatitis. Viral Hepatitis Surveillance, United States, 2011 (accessed online at: http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/PDFs/2011HepSurveillanceRpt.pdf)

ⁱⁱ Mahajan R, et al., “Chronic Hepatitis Cohort Study (CHeCS) Investigators. Mortality Among Persons in Care with Hepatitis C Virus Infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010,” Clinical Infectious Diseases, 2014.

ⁱⁱⁱ Product label of PEGASYS, peginterferon alfa-2a (http://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm094462.pdf, accessed on 7/3/2014)

^iv Tice J, et al., “The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the treatment of Chronic Hepatitis C infection, A Technology Assessment,” California Technology Assessment Forum, 2014.

^v Epidemiological modeling by the Center for Disease Analysis (unpublished).

^vi Nainan OV, et al., “Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States,” Gastroenterology, 2006.

^vii Chak E, et al., “Hepatitis C Virus Infection in USA: An Estimate of True Prevalence,” Liver International, February 2011.

^viii Koh HK, et al., “Hepatitis C Virus Infection in Young Persons Who Inject Drugs,” Technical Consultation, 2013 (http://aids.gov/pdf/hcv-and-young-pwid-consultation-report.pdf, accessed on 7/3/2014)

^ix Armstrong GL, et al., “The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002,” Annals of Internal Medicine, 2006.

^x Pyenson B,et al., Healthcare reform and hepatitis C: A convergence of risk and opportunity, Milliman Associates, 2013.

^xi US CDC, Hepatitis C Factsheet (http://www.cdc.gov/hepatitis/hcv/pdfs/hepcgeneralfactsheet.pdf, accessed on 7/3/2014)

^xii Rein DB, et al., “The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings,” Annals of Internal Medicine, 2012.

^xiii American Liver Foundation website (http://hepc.liverfoundation.org/, accessed on 7/3/2014)

^xiv Transplant living (http://www.transplantliving.org/before-the-transplant/financing-a-transplant/the-costs/, accessed on 7/14/2014)

^xv Edlin BR. “Perspective: Test and Treat This Silent Killer.” Nature, 2011.

^xvi Ly KN, et al., “The Increasing Burden of Mortality from Viral Hepatitis in the United States between 1999 and 2007,” Annals of Internal Medicine, 2012.

^xvii U.S. CDC HIV and Viral Hepatitis Fact Sheet (http://www.cdc.gov/hepatitis/Populations/PDFs/HIVandHep-FactSheet.pdf, accessed on 7/3/2014)

^xviii Strader DB, et al., “A Brief History of the Treatement of Viral Hepatitis C,” Clinical Liver Disease, 2012

^xix Bruno S, et al., “Sustained Virologic Response Prevents the Development of Esophageal Varices in Compensated, Child-Pugh Class A Hepatitis C Virus-Induced Cirrhosis. A 12-year prospective follow-up study,” Hepatology, 2010.

^xx van der Meer AJ, et al., “Association Between Sustained Virological Response and All-Cause Mortality Among Patients with Chronic Hepatitis C and Advanced Hepatic Fibrosis,” Journal of the American Medical Association, 2012.

^xxi LaFleur J, et al., “High Rates of Early Treatment Discontinuation in Hepatitis C-Infected US Veterans,” BMC Res Notes, 2014.

^xxii Brennan and Shrank, “New Expensive Treatments for Hepatitis C Infection,” Journal of the American Medical Association, 2014.

^xxiii Razavi H, et al., “The Present and Future Disease Burden of Hepatitis C Virus (HCV) Infection with Today’s Treatment Paradigm,” Journal of Viral Hepatology, 2014.

^xxiv Heathcote EJ, et al. “Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis,” New England Journal of Medicine, 2000.

Download the full report here